Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (14,6 Mio. €): Europäische Infrastruktur für Impfstoffforschung und -entwicklung Hor01.05.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Europäische Infrastruktur für Impfstoffforschung und -entwicklung
TRAN???C2 is the follow-up project to its successful predecessor project TRAN???C, the European Network of Vaccine Research and Development funded under FP7. The TRAN???C2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRAN???C2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRAN???C2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRAN???C2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of TRAN???C2 will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of TRAN???C2 with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Academisch Ziekenhuis Leiden | 555.000 € |
| 191.903 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 1.513.270 € |
| 660.499 € | |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 288.000 € |
| EUROPEAN VACCINE INITIATIVE e. V. | 1.309.122 € |
| 261.831 € | |
| Ecrin European Clinical Research Infrastructure Network | 226.750 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 518.904 € |
| 108.993 € | |
| HELMHOLTZ-ZENTRUM für INFEKTIONSFORSCHUNG GmbH | 486.691 € |
| 916.708 € | |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 202.284 € |
| Institut de Recerca i Tecnologia Agroalimentaries | 729.867 € |
| Instruct Academic Services Ltd. | 29.260 € |
| 138.599 € | |
| Istituto Superiore DI Sanita | 0,00 € |
| 130.833 € | |
| Masarykova Univerzita | 0,00 € |
| 196.377 € | |
| 75.320 € | |
| Statens Serum Institut | 645.028 € |
| Stichting Biomedical Primate Research Center | 2.576.814 € |
| Stichting Wageningen Research | 471.015 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 640.595 € |
| 0,00 € | |
| UNIVERSITE DE LAUSANNE | 0,00 € |
| Universita Degli Studi DI Siena | 738.243 € |
| Universiteit Leiden | 235.450 € |
| Vaccine Formulation Institute Ltd. | 709.379 € |
Quelle: https://cordis.europa.eu/project/id/730964
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Academisch Ziekenhuis Leiden - EU-Förderung (14,6 Mio. €): Europäische Infrastruktur für Impfstoffforschung und -entwicklung"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
